We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Emerging Strategies in Adjuvant Immunotherapy: A Comparative Review of Bladder Cancer and Renal Cell Carcinoma Treatments.
- Authors
Balli, Sevinc; Bolek, Hatice; Ürün, Yüksel
- Abstract
Recent progress in adjuvant immunotherapy offers hope for improving disease-free survival in high-risk bladder cancer (BC) and renal cell carcinoma (RCC). This review focuses on key trials such as CheckMate 274 and KEYNOTE-564, which show promising results with nivolumab in BC and pembrolizumab in RCC, including a 30% reduction in progression risk. Pembrolizumab also demonstrated overall survival (OS) benefit in RCC. The review also explores the potential of circulating tumor DNA (ctDNA) as a biomarker for better therapy selection and patient stratification. It emphasizes the need for ongoing research to establish survival benefits and suggests integrating biomarkers and risk stratification to optimize adjuvant immunotherapy in BC and RCC.
- Subjects
NUCLEIC acid analysis; BLADDER tumors; IMMUNOTHERAPY; CLINICAL trials; TUMOR markers; MONOCLONAL antibodies; IMMUNE checkpoint inhibitors; RENAL cell carcinoma; DRUG efficacy; NIVOLUMAB; PROGRESSION-free survival; EXTRACELLULAR space; DISEASE progression; OVERALL survival
- Publication
Clinical Medicine Insights: Oncology, 2024, p1
- ISSN
1179-5549
- Publication type
Article
- DOI
10.1177/11795549241257238